Anesiva's media center is designed to provide reporters with easy access to news about the company and its products for stories in development. If you don't find what you are looking for or need more information, please contact us.
All Releases |
|
Corgentech Plans to Expand Clinical Product Pipeline With Phase 1/2 Trial of NF-KB Decoy in Eczema
Sep 22, 2004
|
76.0 KB
|
|
SOUTH SAN FRANCISCO, Calif., Sep 22, 2004 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, today announced that it plans to initiate a Phase 1/2 clinical trial in the first half of 2005 in eczema with NF-Kappa-B Decoy (NF-KB Decoy), a highly selective and potent inhibitor of immune and inflammatory res...
|
|
|
Corgentech to Host Product Pipeline Update on September 22, 2004
Sep 9, 2004
|
71.5 KB
|
|
SOUTH SAN FRANCISCO, Calif., Sep 9, 2004 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, today announced that it will be hosting an investor briefing to discuss its pipeline beyond current product trials on Wednesday, September 22, 2004 from 9:30 a.m. to 12 p.m. in New York City. The briefing will be...
|
|
|
Corgentech To Present At Bear Stearns 17th Annual Healthcare Conference
Sep 7, 2004
|
45.6 KB
|
|
SOUTH SAN FRANCISCO, Calif., September 7, 2004 -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, today announced that John McLaughlin, the company's president and chief executive officer, will present at the Bear Stearns 17th Annual Healthcare Conference on Monday, September 13, 2004 at 2:45 p.m. EDT at The Plaza Hotel in New York. He ...
|
|
|
Corgentech to Present at NewsMakers in the Biotech Industry Conference
Sep 2, 2004
|
68.2 KB
|
|
SOUTH SAN FRANCISCO, Calif., Sep 2, 2004 (BUSINESS WIRE) -- Corgentech Inc. (NASDAQ:CGTK), a biotechnology company, today announced that John McLaughlin, the company's president and chief executive officer, will present at NewsMakers in the Biotech Industry Conference on Thursday September 9, 2004 at 10:30 a.m. EDT at the Millennium Broadway Hotel...
|
|
|
Corgentech Announces Patent Issuance for E2F Transcription Factor Decoy Technology
Aug 17, 2004
|
68.5 KB
|
|
SOUTH SAN FRANCISCO, Calif., Aug 17, 2004 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 6,774,118. The patent covers a method for preventing formation of neointimal thickening leading to restenosis...
|
|
|